Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MST-168 in Advanced Solid Tumors
NCT07644650Phase 1Recruiting
- Sponsor
- Mabsoft Therapeutics
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of MST-168 in solid tumor (6 arms), sponsored by Mabsoft Therapeutics. Primary endpoints: Dose-Limiting Toxicities and Adverse Events up to 25 months. Started Oct 2026; status: recruiting.
02
Drugs
MST-168
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07644650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644650.